{"id":"ecabet-2-83","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T02:36:24.419Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123837,"model":"claude-sonnet-4-5-20250929"},"description":"Ecabet 2.83% is an investigational ophthalmic formulation being developed by Bausch & Lomb Incorporated. Currently in Phase 2 clinical trials, this topical agent is being evaluated for potential therapeutic applications in eye care, though specific indications have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Ophthalmic condition (unspecified)","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT00370747","phase":"PHASE2","title":"Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-09","conditions":"Dry Eye Syndromes","enrollment":162},{"nctId":"NCT00198536","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-04","conditions":"Dry Eye Syndromes","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Ecabet 2.83%","genericName":"Ecabet 2.83%","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","firstApprovalDate":"","aiSummary":"Ecabet is a small molecule used in an ophthalmic solution for treating Dry Eye Syndromes. It is available in a concentration of 2.83% as part of a clinical study to evaluate its efficacy and safety.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}